View Item 

Show simple item record

Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis
dc.contributor.authorShiozawa, Yusukeen_US
dc.contributor.authorMcGee, Samanthaen_US
dc.contributor.authorPienta, Michael J.en_US
dc.contributor.authorMcGregor, Natalieen_US
dc.contributor.authorJung, Younghunen_US
dc.contributor.authorYumoto, Kenjien_US
dc.contributor.authorWang, Jingchengen_US
dc.contributor.authorBerry, Janice E.en_US
dc.contributor.authorPienta, Kenneth J.en_US
dc.contributor.authorTaichman, Russell S.en_US
dc.date.accessioned2013-10-02T15:13:25Z
dc.date.available2015-01-05T13:54:44Zen_US
dc.date.issued2013-11en_US
dc.identifier.citationShiozawa, Yusuke; McGee, Samantha; Pienta, Michael J.; McGregor, Natalie; Jung, Younghun; Yumoto, Kenji; Wang, Jingcheng; Berry, Janice E.; Pienta, Kenneth J.; Taichman, Russell S. (2013). "Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis." Journal of Cellular Biochemistry 114(11): 2471-2478.en_US
dc.identifier.issn0730-2312en_US
dc.identifier.issn1097-4644en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/100159
dc.description.abstractErythropoietin (Epo) is used in clinical settings to enhance hematopoietic function and to improve the quality of life for patients undergoing chemotherapy by reducing fatigue and the need for transfusions. However, several meta‐analyses have revealed that Epo treatments are associated with an increased risk of mortality in cancer patients. In this study, we examined the role of Epo in prostate cancer (PCa) progression, using in vitro cell culture systems and in vivo bone metastatic assays. We found that Epo did not stimulate the proliferation of PCa cell lines, but did protect PCa cells from apoptosis. In animal models of PCa metastasis, no evidence was found to support the hypothesis that Epo enhances metastasis. Together, these findings suggest that Epo may be useful for treating severe anemia in PCa patients without increasing metastatic risk. J. Cell. Biochem. 114: 2471–2478, 2013. © 2013 Wiley Periodicals, Inc.en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCANCERen_US
dc.subject.otherTUMORen_US
dc.subject.otherGROWTHen_US
dc.subject.otherMETASTASISen_US
dc.subject.otherPROSTATEen_US
dc.subject.otherERYTHROPOIETINen_US
dc.titleErythropoietin supports the survival of prostate cancer, but not growth and bone metastasisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbsecondlevelGeneticsen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/100159/1/jcb24592.pdf
dc.identifier.doi10.1002/jcb.24592en_US
dc.identifier.sourceJournal of Cellular Biochemistryen_US
dc.identifier.citedreferenceShiozawa Y, Taichman RS. 2012. Getting blood from bone: An emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche. Exp Hematol 40: 685 – 694.en_US
dc.identifier.citedreferenceDunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR. 2006. Induction of signalling in non‐erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 3: 94 – 100.en_US
dc.identifier.citedreferenceFandrey J, Dicato M. 2009. Examining the involvement of erythropoiesis‐stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist 14 (Suppl 1): 34 – 42.en_US
dc.identifier.citedreferenceFeldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. 2006. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66: 135 – 145.en_US
dc.identifier.citedreferenceFinucane ML, Slovic P, Mertz CK. 2000. Public perception of the risk of blood transfusion. Transfusion 40: 1017 – 1022.en_US
dc.identifier.citedreferenceFolkman J. 1995. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757 – 1763.en_US
dc.identifier.citedreferenceGay LJ, Felding‐Habermann B. 2011. Contribution of platelets to tumour metastasis. Nat Rev Cancer 11: 123 – 134.en_US
dc.identifier.citedreferenceHedley BD, Allan AL, Xenocostas A. 2011. The role of erythropoietin and erythropoiesis‐stimulating agents in tumor progression. Clin Cancer Res 17: 6373 – 6380.en_US
dc.identifier.citedreferenceHeeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner‐Rihm C, Martin H, Zeiher AM, Dimmeler S. 2003. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340 – 1346.en_US
dc.identifier.citedreferenceIngber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555 – 557.en_US
dc.identifier.citedreferenceJelkmann W, Elliott S. 2012. Erythropoietin and the vascular wall: The controversy continues. Nutr Metab Cardiovasc Dis In Press.en_US
dc.identifier.citedreferenceJelkmann W, Laugsch M. 2007. Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol 25: 1627 – 1628, author reply 1628.en_US
dc.identifier.citedreferenceJeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ. 2008. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 122: 274 – 280.en_US
dc.identifier.citedreferenceJubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. 1997. The beta chain of the interleukin‐3 receptor functionally associates with the erythropoietin receptor. Blood 90: 1867 – 1873.en_US
dc.identifier.citedreferenceKataoka M, Moriya Y, Moriguchi Y, Iwai T, Fujimoto‐Ouchi K, Shirane M, Kondoh K, Mori K. 2010. Effect of erythropoietin on human tumor growth in xenograft models. Mol Med Rep 3: 95 – 101.en_US
dc.identifier.citedreferenceLeyland‐Jones B. 2003. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459 – 460.en_US
dc.identifier.citedreferenceMuller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50 – 56.en_US
dc.identifier.citedreferenceO'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315 – 328.en_US
dc.identifier.citedreferenceO'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277 – 285.en_US
dc.identifier.citedreferenceRibatti D. 2010. Erythropoietin and tumor angiogenesis. Stem Cells Dev 19: 1 – 4.en_US
dc.identifier.citedreferenceShiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, Song J, Wang J, Lee CH, Sud S, et al. 2010. Erythropoietin couples hematopoiesis with bone formation. PLoS ONE 5: e10853.en_US
dc.identifier.citedreferenceShiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. 2011. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121: 1298 – 1312.en_US
dc.identifier.citedreferenceSinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S, Begley CG. 2010. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115: 4264 – 4272.en_US
dc.identifier.citedreferenceSpivak JL, Gascon P, Ludwig H. 2009. Anemia management in oncology and hematology. Oncologist 14 (Suppl 1): 43 – 56.en_US
dc.identifier.citedreferenceSun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J. 2010. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29: 709 – 722.en_US
dc.identifier.citedreferenceTaichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. 2002. Use of the stromal cell‐derived factor‐1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832 – 1837.en_US
dc.identifier.citedreferenceVisnjic D, Kalajzic I, Gronowicz G, Aguila HL, Clark SH, Lichtler AC, Rowe DW. 2001. Conditional ablation of the osteoblast lineage in Col2.3deltatk transgenic mice. J Bone Miner Res 16: 2222 – 2231.en_US
dc.identifier.citedreferenceVisnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. 2004. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 103: 3258 – 3264.en_US
dc.identifier.citedreferenceWestenfelder C, Baranowski RL. 2000. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647 – 657.en_US
dc.identifier.citedreferenceWright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, et al. 2007. Randomized, double‐blind, placebo‐controlled trial of erythropoietin in non‐small‐cell lung cancer with disease‐related anemia. J Clin Oncol 25: 1027 – 1032.en_US
dc.identifier.citedreferenceWu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. 1998. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate‐specific antigen‐producing tumors in athymic and SCID/bg mice using LNCaP and lineage‐derived metastatic sublines. Int J Cancer 77: 887 – 894.en_US
dc.identifier.citedreferenceYasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, et al. 2003. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021 – 1029.en_US
dc.identifier.citedreferenceAcs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. 2001. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561 – 3565.en_US
dc.identifier.citedreferenceArcasoy MO. 2008. The non‐haematopoietic biological effects of erythropoietin. Br J Haematol 141: 14 – 31.en_US
dc.identifier.citedreferenceArcasoy MO, Jiang X, Haroon ZA. 2003. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 307: 999 – 1007.en_US
dc.identifier.citedreferenceArcasoy MO, Amin K, Vollmer RT, Jiang X, Demark‐Wahnefried W, Haroon ZA. 2005. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 18: 421 – 430.en_US
dc.identifier.citedreferenceBahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. 2004. Erythropoietin regulates endothelial progenitor cells. Blood 103: 921 – 926.en_US
dc.identifier.citedreferenceBrines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su‐Rick CJ, et al. 2004. Erythropoietin mediates tissue protection through an erythropoietin and common beta‐subunit heteroreceptor. Proc Natl Acad Sci USA 101: 14907 – 14912.en_US
dc.identifier.citedreferenceCalvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, et al. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841 – 846.en_US
dc.identifier.citedreferenceDempke W, Von Poblozki A, Grothey A, Schmoll HJ. 2000. Human hematopoietic growth factors: Old lessons and new perspectives. Anticancer Res 20: 5155 – 5164.en_US
dc.identifier.citedreferenceDicato M, Plawny L. 2010. Erythropoietin in cancer patients: Pros and cons. Curr Opin Oncol 22: 307 – 311.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jcb24592.pdf
Size:
1.312MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.